MPN

After finding out she had an MPN, Barbara Abernathy, Ph.D., like many other people, felt numb. But then it was time to find her fight mode.

With the study of more biomarkers for MPNs, the field continues to advance. However, more work still needs to be done.

Tavalisse (fostamatinib) was granted approval by the Food and Drug Administration (FDA) for patients with chronic immune thrombocytopenia (ITP) after they had an insufficiencent response to another therapy.

Findings from a phase 3 randomized clinical trial offer new hope to some patients who have advanced myelofibrosis.

Patients with PV tend to be very symptomatic, but Jakafi can help.

Ruben Mesa, M.D., director of the UT Health San Antonio Cancer Center, discusses complementary therapy for patients with myeloproliferative neoplasms (MPNs).

Nutritional change may be a potential strategy to improve symptom burden and inflammation in patients with MPNs, whohave increased inflammatory cytokines, which contribute to symptoms such as fatigue, night sweats and bone pain, as well as low cholesterol and weight loss related to nutritional deficiencies.

For more than 20 years, Barbara Abernathy, Ph.D., has been living with cancer and its aftermath. She was diagnosed with a rare type of blood cancer collectively known as myeloproliferative neoplasms (MPNs), which transitioned into acute myeloid leukemia. In 2013, she underwent a stem cell transplantation — a lifesaving gift from a young man in Germany.

For years, many health care professionals noticed that patients with myeloproliferative neoplasms (MPNs) tend to experience thrombosis more than the average person. Now, a recent population-based study conducted in Sweden confirmed their suspicions.